Dr. Reddy's Laboratories Ltd. closed 18.89% below its 52-week high of 1,420.20 rupees, which the company reached on August ...

As the director of statistical programming and biostatistics at Epis Data Inc., Srinivasa Reddy Mukkala accelerates ...

Dr. Reddy's Laboratories Ltd. closed 17.55% below its 52-week high of 1,420.20 rupees, which the company achieved on August ...

An analyst from YES Securities said that Vedanta has faced downward pressure, leading to a gradual decline in its stock price ...

Dr. Reddy's Laboratories may be undervalued with mixed growth prospects, but the 5 analysts following the company give it an rating of hold. Their target prices range from $13.08432 to $19.443024 per ...

Allspring Global Investments Holdings LLC grew its holdings in Dr. Reddy’s Laboratories Limited (NYSE:RDY – Free Report) by ...

Indian shares opened on a sluggish note Monday amid fresh tariff and inflation jitters after a measure of U.S. inflation expectations ...

Dr. Reddy's Laboratories DRREDDY RDY has delivered a set of financial results. For the third quarter (Q3FY25) and the nine months (9MFY25) ending December 31, 2024, the company showcased robust ...

Dr. Reddy’s Laboratories will develop and commercialise Shanghai Henlius Biotech’s biosimilar candidate to Johnson & Johnson’s multiple myeloma drugs Darzalex and Darzalex Faspro.

To Pay Chinese player up to $131.6 million for subcutaneous & intravenous formulations of HLX15 “The agreement combines Dr Reddy’s global commercial presence with Henlius’ proven ...

Dr Reddys Laboratories Ltd is quoting at Rs 1241.5, up 1.14% on the day as on 12:49 IST on the NSE. The stock is up 0.45% in last one year as compared to a 7.61% jump in NIFTY and a 18.78% jump in the ...

Dr Reddy's Laboratories subsidiary signs licence agreement with Shanghai Henlius Biotech for development and commercialization of HLX15, an under-development cancer drug. New Delhi, Feb 6 (PTI) Dr ...